In this updated classification, the requirement of 20% blasts is not necessary for diagnosing AML in the presence of specific genetic abnormalities (Table 1), except for AML with BCR-ABL1 fusion, AML with CEBPA mutation, and those harboring other rare genetic alterations, which still require 20% blasts. The gene discussed is CEBPA; the disease is acute myeloid leukemia.